Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
New Drug Proves Effective Against Rare Skin Cancer | |
|
| |
A novel drug fights rare skin cancer, say researchers.
The drug, Erivedge (vismodegib), is made by Genentech, a US subsidiary of the Swiss drug giant Roche, and was approved by the US Food and Drug Administration in January after an expedited review.
The drug, Erivedge (vismodegib), is made by Genentech, a US subsidiary of the Swiss drug giant Roche, and was approved by the US Food and Drug Administration in January after an expedited review.
It aims to treat basal cell carcinoma, which is the most common form of skin cancer in the world but which is rarely deadly. Basal cell carcinoma accounts for 80 percent of nonmelanoma cancers and some two million new cases in the US each year.
The journal published two studies that show how it helped some patients with two unusual variations of basal cell carcinoma: metastatic basal cell carcinoma and Gorlin syndrome, also known as Basal Cell Nevus Syndrome.
There is no other treatment for Gorlin syndrome, which strikes one in 50,000 people and involves the constant growth of tumors, which are often not deadly but can cause scarring and require frequent surgeries.
Subjects with Gorlin syndrome who took vismodegib developed an average of two new tumors per year, compared with 29 new tumors in subjects taking a placebo, the study said.
When it came to people whose basal cell carcinoma had spread, the study showed 30 percent of 33 patients with metastatic basal cell carcinoma responded to treatment, meaning their tumors shrank.
Forty-three percent of 63 subjects with locally advanced basal cell carcinoma responded in kind.
The phase II study showed a median progression-free survival time of 9.5 months, but overall survival rates have not yet been established.
"It is a landmark day for patients with basal cell carcinoma and all those involved in their care -- the greatest advance in therapy yet seen for this disease," said an accompanying editorial by John Lear, consultant dermatologist at Manchester Royal Infirmary in Britain.
However, he pointed out the high rate of adverse effects, including loss of taste, hair loss and muscle cramps, which led to a high rate of people dropping out of the study early.
"Side effects are considerable and frequent, resulting in high rates of drug discontinuation, and these rates will probably be even higher in clinical practice," Lear said.
More study is needed to determine how long the drug may work to ward off cancer, what populations it may best serve, and when it should be optimally administered, he added.
Source-AFP
| |
|
|
More News on: Drug Toxicity, Skin Cancer , Cancer and Homeopathy, Clinical Trials - Different Phases of the trial , Ultra-Violet Radiation , Signature Drug Toxicity, Cancer Facts, Pityriasis rosea, Cancer, Tattoos A Body Art
 Comment & Contribute
|
Related Links
Skin Cancer
Latest information on skin cancer, skin cancer types, risk factors and causes. Aspects related to skin cancer symptoms, diagnosis, treatment and ...
Melanoma
Melanoma is the most dangerous type of skin cancer. It is a cancer that develops in melanocytes, cells which produce a skin pigment called ...
Drug for Melanoma Shows Promise in Early Trial
An experimental drug for melanoma has successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international ...
Drug Related News
Link Between Calcium Supplements and Longer Lifespan Identified
Intake of calcium supplements can help women live longer, says study published in Journal of Clinical Endocrinology & Metabolism (JCEM). ...
Experts Recommend US Approval of a New Merck Sleeping Pill
Independent panel of experts recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage ...
Common Drug for Depression Reduces Stress-related Heart Condition
Researchers at Duke Medicine have found that a drug commonly used to treat depression and anxiety may improve a stress-related heart condition in ...
New, Effective Sleeping Pill from Merck to Hit US Markets
An experimental sleeping pill from US drug company Merck is effective at helping people fall asleep and stay asleep, say reviewers at the US Food and ...
EU Agency Says Acne Pill Benefits Outweigh Blood Clot Risk
The benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins, said Europe's ...
Reduce Ambien's Dose to Avoid Drowsy Driving
U.S. Food and Drug Administration has now given the nod for new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) with a view to ...
Medwonders Health Network
- Health News Index
|
|
 | Quiz on Cancer Looking for information on cancer? Go through medindia's Cancer quiz. 
|
- News Quick Links
 |
Cancer
Complete Medindia Resources
|
| News Categories: |
| » | Potatoes may be One of the Best Superfoods, Says Study |
| » | Amount of Calories in Fast Foods Underestimated by People |
| » | GM Tomatoes 'Tastier and Longer-lasting' |
| » | Dietary Advice on Added Sugar 'Damaging Our Health', Says Expert |
| » | What is the Similarity Between Sugary Syrup and Cocaine? |
| More Diet News | |
|
Ask an Expert
